Dr. Eddie Y. K. NgPhD, PGDTHE, FEASA [EU], FASME [USA], FIETI [HK], FIET [UK], DFIDSAI [CN], Nanyang Technological University, Singapore
Speech Title: High Contrast Vein Visualization with Active Dynamic Thermography (ADT)
Abstract: In this talk, a novel method that will aid in the visualization of vein topology on a target area on the body of a human subject is presented. An external cooling means is configured to cool the left forearm of fourteen study participants, effecting an active thermal change or recovery in the target area upon removal of cooling. An infrared (IR) thermal camera was used to capture a series of transient thermal images. These images were then processed to extract Dynamic Synthetic Images (SI) throughout the active thermal change or recovery process. Dynamic SI was calculated using a new quantitative parameter named Tissue Activity Ratio (TAR), defined by the rate of rewarming to the rate of cooling at each pixel of interest. A fixed step size of rewarming temperature (0.5 ) was used to progressively extract multiple synthetic images throughout the whole recovery process. Compared to a Static SI extraction method, where only a single SI results from the whole active dynamic thermography (ADT) sequence, our study demonstrates a live feed of high contrast vein visualizations by using the novel Dynamic SI method. The dependency of Dynamic SI contrast on the temperature of the external cooling stimulation was investigated. Three cooling stimulation temperatures (5 , 8 , and 11 ) were tested, where no statistically significant difference in the resulting SI contrast was found. In all, I will discuss on assisting venipuncture or cannulation-based clinical applications, through the incorporation of the proposed method with a projection system.
Keywords: Active Dynamic Thermography; Image Contrast; Tissue Activity Ratio (TAR); Thermal Image Reconstruction; Vein Visualization; Vein Projection; Venepuncture
Saxena and Ng et al, "A Method to Produce High Contrast Vein Visualization in Active Dynamic Thermography (ADT)", Computers in Biology and Medicine, (2021), Vol. 132, pp. 104309 (9 pages), https://doi.org/10.1016/j.compbiomed.2021.104309
Eddie is elected as:
* Academician for European Academy of Sciences and Arts (EASA, EU);
* Fellow of the American Society of Mechanical Engineers (FASME, USA);
* Fellow of Institute of Engineering and Technology (FIET, United Kingdom);
* Fellow of International Engineering and Technology Institute (FIETI, Hong Kong),
* Distinguished Fellow for Institute of Data Science and Artificial Intelligence,
* (DFIDSAI, China), and,
* Academician for Academy of Pedagogy and Learning, (USA).
He has published numerous papers in SCI-IF int. journal (430); int. conf. proceedings (130), textbook chapters (>105) and others (32) over the 29 years. Co-edited 14 books in STEM areas.
He is in the Stanford list of the World’s top 2% Scientists since 2019 (ranked 173 as 0.001% in the field of Biomedical Engineering).
He is the:
* Lead Editor-in-Chief for the ISI Journal of Mechanics in Medicine and Biology for dissemination of original research in all fields of mechanics in medicine and biology since 2000;
* Founding Editor-in-Chief for the ISI indexed Journal of Medical Imaging and Health Informatics;
* Associate editor or EAB of various referred international journals such as Applied Intelligence, BioMedical Engineering OnLine, Computers in Biology & Medicine, and, Journal of Advanced Thermal Science Research.
More details can be found in: Cv: https://dr.ntu.edu.sg/cris/rp/rp00847.
Ng obtained Ph.D. at Cambridge Univ. and elected as an Academician for European Academy of Sciences and Arts, a Fellow of The American Society of Mechanical Engineers; The Institution of Engineering and Technology [UK], and International Engineering & Technology Institute [HK]. He researches in numerical simulation in the biomedical engineering, thermal-fluids and health-related diagnosis fields. He is Editor-in-Chief for 2 ISI-journals which were captured by the JCR within 2-years of their inauguration. He has been recognized internationally for academic excellence. He received numerous best papers, service awards and has graduated 23 PhD and 26 Master students. He was awarded the SPRING-Singapore Merit Award for his work in thermal imagers to screen SARS fever and contributions to the Singapore Standardization Program. Twenty-one of his papers have been adopted as references in Singapore Standard (SS-582, Parts 1&2: 2020) and ISO/IEC 80601-2-59: 2017. He serves as a panel member for Singapore Biomedical and Health Standards Committee since 2011. Being a co-inventor of 3 US patents on software classifiers to identify the different stages of breast cancer development in iTBra-system, he was accoladed with equity in a listed company. His ongoing work on non-contact screening for carotid artery stenosis and superficial vein-finder has resulted in 3 TDs. He has notable citations in the field of infrared physics & technology.
Dr. Alan MenterChairman
Division of Dermatology, Baylor University Medical Center, USA
Speech Title: Psoriasis: update on Biologic Agents
Abstract: The development of new biologic agents for the treatment of moderate-to-severe psoriasis has taken a major advance over the past decade. The original biologic drugs were the TNF- α agents, i.e. Etanercept, Adalimumab, Certolizumab and Infliximab, all of which were first approved, prior to psoriasis, for psoriatic and rheumatoid arthritis. Subsequently, after the advent of Ustekinumab, the only IL 12-23 agent, 6 new biologic agents, i.e. IL-17 and IL-23 antagonists have been approved for moderate-to-severe psoriasis, with excellent clinical efficacy as well as high quality safety.
In 2019, the American Academy of Dermatology along with the National Psoriasis Foundation published a full and lengthy review of updated Guidelines for the management and treatment of psoriasis with biologic agents. Three IL-inhibitors, i.e. Secukinumab, Ixekizumab, and Brodalumab, as well as three IL-23 inhibitors, Tildrakizumab, Guselkumab and Risankizumab were all fully discussed, along with clinical trial data of all 6 agents.
A number of then original biologic agents, i.e. the 4 TNF-α agents have now lost their patent protection with exactly equivalent biosimilar products available world-wide, at considerable (30-40%) price reduction.
Thanks to modern science, even complex molecules like the biologic psoriasis drugs can be developed as biosimilars today.
Keywords: biologic agent, IL 17, IL-23, Psoriasis, biosimilars
Biography: Dr. Alan Menter was born in England and is a graduate of the Medical School of the University of Witwatersrand, South Africa. He completed his dermatology residency at Pretoria General Hospital at the University of Pretoria, also in South Africa, and two fellowships in London at Guy's Hospital and St. John's Hospital for Diseases of the Skin.
A fellowship with the University of Texas Southwestern Medical Center in Dallas brought Menter to the United States in 1975. Since then, he has held several positions within the UT and Baylor University Dallas systems. In 1992, he was appointed chairman of the Division of Dermatology at Baylor University Medical Center and still holds that position. In 2007, he was appointed director of the Baylor Research Center and in 2010, Program Director of the newly formed Dermatology Residency Program at Baylor University Medical Center.
Committed to patients
Dr. Menter has a long-held interest in psoriasis and psoriatic disease research. In 1994, he co-authored the first gene discovery for psoriasis, published in Science in 1994. His research on psoriasis has examined everything from ultraviolet phototherapy, new biologic therapy to the mapping of genetic patterns to predict if a person is at risk of developing psoriasis pharmacogenomics.
In August 2004, Dr. Menter helped found the International Psoriasis Council to raise international awareness of psoriasis as a serious autoimmune disease that can significantly impact quality of life. His clinical practice includes more than 1,800 patients on systemic and biologic therapy.
Dedicated to research
Dr. Menter held the position of clinical director of the National Psoriasis Foundation Gene Bank from 1996 to 2002. His resume lists some 385+ articles, 6 books and 21 book chapters. He serves as a member of the editorial board for several medical journals, including the Journal of Clinical Dermatology and Clinical and Experimental Dermatology. He is Dermatology Chair at Baylor Scott & White, Dallas and Program Director our Dermatology Residency Program as well as clinical professor of dermatology at the University of Texas Southwestern Medical School in Dallas and professor at Texas A&M Health Science Center, College of Medicine.
Dr. Menter has been listed in the Best Doctors in America since 1994 and Who’s Who in Medicine and Healthcare since 1996. He also represented the South African National Rugby team, the Springboks, in 1968. In 2013, Dr. Menter received the Lifetime Achievement Award from the National Psoriasis Foundation. In March 2015, he received the Dermatology Foundation annual Clark W. Finnerud award at the AAD meeting in San Francisco. Dr. Menter also received the Preseidential Citation March 2016 and 2018 at the AAD meetings.